LY3154207
Phase 2Small molecule
Eli LillyLY3154207 is one of 10 small molecule programs targeting Lewy body dementia. It is currently in Phase 2.
1
Indications
7
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Lewy Body Dementia
#DrugCompanyPhaseTrials
1Exelon
NovartisApproved
Bosulif
PPrism Pharmaceuticals
Approved
Reminyl
WWim Janssens
Approved
Tasigna
AAzurity Pharmaceuticals
Approved
ACP-204
AACADIA Pharmaceuticals Inc.
Phase 3
Datscan
NNavidea Biopharmaceuticals
Phase 3
Ambroxol Hydrochloride
Boehringer IngelheimPhase 2
Nelotanserin
AAxovant Sciences Ltd.
Phase 2
LY3154207
Eli LillyPhase 2
Donepezil Hydrochloride
EisaiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Parkinson's Disease1 trial
Lewy body dementia1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LY3154207. EMBL-EBI & Wellcome Sanger Institute.
- [4]